While some of our competitors have said they only want to participate in the premium segment, it’s not a large enough segment. We’ll get economies at scale. And at the end of the day, while people are focused on our margin percent, the dollars matter, that’s what you take to the bank. And we are continuing to grow our overall gross margin dollars. So I feel comfortable that the market — we will have some further consolidation. We’ve seen some companies go into CCAA, we’ve seen some shutter facilities over the last while. This is going to be an interesting next 12 months in the market. We’re comfortable in our position, in our improved — we’re projecting improved gross margins, as you’ve heard Derrick say. And we’ll continue to compete in a segment that consumers are finding the right value, so the right quality at a fair price, right?
And so I’m comfortable with our position. In terms of other market share, I mean, we’re growing in the gummies category. We introduced product SHRED-X vapes into a segment that we really haven’t been participating in leveraging our SHRED brand, and saw some nice growth in that segment. We have more opportunities to build on Tremblant hash portfolio because of the strength of that brand and that product. So we do see opportunities in other segments. As Derrick said, we’re predominantly a flower company right now, and we have great assets that give us great quality there. But we continue to build our portfolio and our two acquisitions that we completed in the last year really have helped us expand our portfolio to some higher margin.
Matt Bottomley: Got it. Thanks. I think I might have dropped maybe not. But if I’m still on the line, just one more follow-up for me, I know you touched on this a little bit, but I just want to make sure I understand the cadence of what’s in your guidance as well. So given calling for a significant increase in adjusted EBITDA over the last fiscal year. I’m just wondering if you think that the sort of run rate that you’re at now, or at least the 3.2 million that you did in this quarter, are you expecting to continually see gains sequentially or do you think there’ll be some volatility in terms of being breakeven and sort of up and above that sort of breakeven level?
Derrick West: Yes, with regards to the EBITDA, we do expect significant improvement in fiscal ’23 compared to fiscal ’22. And but I do know that for the first three quarters of fiscal ’22, we were nominally positive and most of the current fiscal ’22 EBITDA do was generated in Q4. We do see EBITDA sequentially improving over next year. There can be some swings. It can depend on mix. But again, generally speaking, with the lower cost of production that we will have for next year and with our sales being at the level that they are, that we think that we can maintain and continue to increase that. Ultimately, we will see that it would increase over the year. But we can’t guarantee one quarter over another at this time. So we’re not giving guidance specifically by quarter, but we would certainly see the year fiscal ’23 being higher than fiscal ’22 in a significant way as a consequence of overall sales being higher and cost of production being much lower than it was for fiscal ’22.
Operator: Our next question comes from the line of Michael Freeman from Raymond James. Your line is open.
Michael Freeman: Congratulations on a terrific quarter, and a really impressive year. So my first question is on capacity. You indicate you’ve completed built out of the 4C expansion in Moncton. You’re continuing to expand cultivation capacity in the Laurentian facility, but with international agreements looking like they’re on a trajectory of growth, there seems to be continued unmet demand in Canada. Do you see even with these capacity expansion projects you’ve been undertaking reaching, running out of capacity to meet demand both domestically and internationally? And if so, what routes might you take to address that?
